AbbVie Reports Positive Phase 3 Results of Skyrizi in Psoriatic Arthritis
By Colin Kellaher
AbbVie Inc. on Tuesday reported positive top-line results from a
pair of Phase 3 studies of its psoriasis treatment Skyrizi in
adults with active psoriatic arthritis.
The North Chicago, Ill., biopharmaceutical company said
significantly more patients treated with Skyrizi achieved the
primary response endpoint in joint symptoms at week 24 versus
AbbVie also said the results of ranked secondary endpoints
showed significant improvements in skin clearance, physical
function and minimal disease activity at week 24.
Skyrizi, which received U.S. and European approval in 2019 for
adults with moderate to severe plaque psoriasis, is part of a
collaboration between AbbVie and Boehringer Ingelheim, a
family-owned pharmaceutical company based in Ingelheim, Germany.
AbbVie leads the global development and commercialization of the
drug, which is also in Phase 3 trials for psoriasis and Crohn's
Write to Colin Kellaher at firstname.lastname@example.org
(END) Dow Jones Newswires
January 05, 2021 09:59 ET (14:59 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.